The Institute for Clinical and Economic Review (ICER) is seeking public feedback on a draft of “proposed adaptations” to its value framework for certain therapies.
ICER, according to a press release, will accept comments until 5 p.m. EST Sept. 6. Feedback should be submitted to firstname.lastname@example.org.
“Cell and gene therapies are starting to provide truly transformative advances for patients and their families, particularly those with conditions for which there has not been any effective treatment before,” said Dr. Steven D. Pearson, ICER’s President. “At the same time, however, many of these therapies are introduced with much higher levels of uncertainty about their long-term safety and effectiveness than standard treatments, and patients and insurers are being asked to pay extremely high prices upfront for the promise of long-term benefit. “
To view the adaptations, click here.